T2 Biosystems (TTOO) Scheduled to Post Earnings on Thursday


Share on StockTwits

T2 Biosystems (NASDAQ:TTOO) will be issuing its quarterly earnings data after the market closes on Thursday, May 6th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

T2 Biosystems (NASDAQ:TTOO) last issued its quarterly earnings results on Wednesday, March 3rd. The medical equipment provider reported ($0.07) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.07). The business had revenue of $7.79 million for the quarter, compared to analyst estimates of $7.78 million. On average, analysts expect T2 Biosystems to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of NASDAQ:TTOO opened at $1.38 on Tuesday. T2 Biosystems has a 1-year low of $0.48 and a 1-year high of $3.79. The stock has a market cap of $204.92 million, a P/E ratio of -2.00 and a beta of 0.72. The company has a debt-to-equity ratio of 2.54, a current ratio of 4.97 and a quick ratio of 4.63. The firm has a fifty day moving average price of $1.54 and a 200 day moving average price of $1.65.

A number of research firms have recently commented on TTOO. Alliance Global Partners reduced their target price on shares of T2 Biosystems from $2.40 to $1.65 and set a “neutral” rating on the stock in a research report on Friday, March 5th. Canaccord Genuity reissued a “buy” rating and set a $3.50 target price on shares of T2 Biosystems in a research report on Tuesday, January 26th. Jonestrading reissued a “buy” rating and set a $3.50 target price on shares of T2 Biosystems in a research report on Wednesday, January 27th. Finally, SVB Leerink dropped their price target on shares of T2 Biosystems from $4.00 to $3.00 and set an “outperform” rating for the company in a research note on Wednesday, January 27th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $2.44.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.

Recommended Story: How Do Tariffs Affect Trade Balances?

Earnings History for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.